Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

18F-fluciclovine PET or PSMA PET for prostate cancer imaging?

Nature Reviews Urology volume 17, pages 9–10 (2020)Cite this article

Subjects

Data from a new study suggests that prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging is superior to 18F-fluciclovine PET for detecting biochemical recurrence in men with prostate cancer. However, whether one of these radiotracers improves patient survival over the other is unknown and further research is needed to determine which has the greater effect.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Simmons, M. N., Stephenson, A. J. & Klein, E. A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur. Urol. 51, 1175–1184 (2007).

    Article  Google Scholar 

  2. Lindenberg, M. L. et al. Imaging locally advanced, recurrent, and metastatic prostate cancer: a review. JAMA Oncol. 3, 1415–1422 (2017).

    Article  Google Scholar 

  3. Mena, E., Lindenberg, L. M. & Choyke, P. L. New targets for PET molecular imaging of prostate cancer. Semin. Nucl. Med. 49, 326–336 (2019).

    Article  Google Scholar 

  4. US Food & Drug Administration. FDA approves new diagnostic imaging agent to detect recurrent prostate cancer. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer (2016).

  5. Calais, J. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286–1294 (2019).

    Article  CAS  Google Scholar 

  6. Savir-Baruch, B. et al. ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin. Nucl. Med. 43, 909–917 (2018).

    Article  Google Scholar 

  7. Tan N. et al. Imaging of prostate specific membrane antigen targeted radiotracers for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. J. Urol. 202, 231–240 (2019).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA

    Baris Turkbey & Peter L. Choyke

Authors
  1. Baris Turkbey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter L. Choyke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baris Turkbey.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turkbey, B., Choyke, P.L. 18F-fluciclovine PET or PSMA PET for prostate cancer imaging?. Nat Rev Urol 17, 9–10 (2020). https://doi.org/10.1038/s41585-019-0255-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0255-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing